The study, published in JAMA, showed that muvalapin lowered levels by up to 85.8% of adults with elevated levels of the lipid. In the trial, participants who received the highest dose of muvalapin showed the most significant reduction in lipoprotein(a) levels, compared to a placebo.
The drug was administered once daily for 12 weeks, with reductions in lipoprotein(a) observed across all three tested doses. The reduction ranged from 47.6% at the lowest dose to 85.5% at the highest.
Secondary endpoints of the trial also showed that muvalapin lowered apolipoprotein B, a protein associated with heart disease, at all tested doses. The drug’s safety profile was consistent with the placebo, with few treatment-related side effects.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
